about
Adoptive immunotherapy for cancer: building on successImaging in the era of molecular oncology.The implication and potential applications of high-mobility group box 1 protein in breast cancerIdentifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensTailoring the Treatment of Melanoma: Implications for Personalized MedicineImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsCD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor ActivityReflections upon human cancer immune responsiveness to T cell-based therapyImmunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificityImpaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma ModelCancer immunotherapy via dendritic cellsCancer immunotherapy comes of ageImmunosuppressive strategies that are mediated by tumor cellsDendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumIn vivo imaging of T cell delivery to tumors after adoptive transfer therapy.Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigenAntitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice.T-cell artificial focal triggering tools: linking surface interactions with cell response.Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medicationNovel approaches for identifying target antigens of autoreactive human B and T cellsT cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.Pathways of antigen processing.Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumorsImmunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapyA novel self-lipid antigen targets human T cells against CD1c(+) leukemiasMucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumorsHIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Bridging innate and adaptive antitumor immunity targeting glycans.Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes
P2860
Q24546258-3E70FF15-1573-4F93-A0C9-4C73DDA37140Q24650949-556EF60B-7BED-4B93-BEF7-80F4C75E956EQ26744069-17D29A8A-578A-4037-8A2E-4C7303E77D7AQ26774669-1A2907F9-A09E-4429-98EC-34229994272EQ26775806-0CD053E7-EF60-4EEB-9498-DC1CA4E56691Q26781538-ABD3D1F0-C0DF-417B-90DF-F8664CE50B4CQ26782520-0ABAD015-A1B2-4D45-A6BF-55B7C7FC2F43Q27004674-F5149B0A-69E1-4BB6-A30D-50C255CB3D0DQ27027633-DD719E50-373B-4992-88A6-F6D5BF1C425FQ27653583-D9C06738-92E6-4140-BCC0-7EE8E9A6382BQ28607232-ABC7E400-BDAE-46C1-B9B8-BD71E7521ED3Q29615444-09E15A1D-4047-4E05-911F-2EC92BDA3A36Q29619918-3CF058DA-8D82-4DBC-B6F7-964FA0C1A50EQ29636247-3C87CC46-2B4A-459D-949C-E0686FE39375Q30318566-CBC08C79-4F96-426C-87C1-04E19F77CF8FQ30439109-7F114F71-1629-4685-93F8-5D0D53879ABFQ30479855-50964177-D82A-4873-A4D4-47ACAFD05FA5Q33303005-E8240D0B-CB47-41B6-90E9-CC7C6BFB54DCQ33322422-C2077F7F-A31F-4119-AC13-11EE31351B4AQ33357299-861E7742-F5C5-4A7E-8EB0-C52F2A551AEDQ33378044-6445C6BC-5DE0-4DCF-A9A5-36B094DF7365Q33398031-782163BD-2EB1-4B38-96D4-3183BABDF22AQ33416441-1F4F3A1A-2D91-4FF6-83FF-A26CD93BE956Q33495754-2686D2B5-E119-43BF-AED2-0B06BFBE39FBQ33504656-48CCE894-B647-48E9-9474-AD9A0D2820B7Q33530527-30FAFB80-8D0C-4D6C-831A-AC0757C0DE8BQ33582300-40D51510-22D5-4C66-B461-FB99826B11AEQ33631854-80148F01-E935-4601-A996-581080F518B0Q33750137-C84F4718-0A62-4189-B508-E6C2FD2909E5Q33750205-ADE5F4EA-F03F-4A61-A89D-09163B9A5DEFQ33761188-A057CE79-72EB-445B-8AFD-C53F1CEBFDBBQ33765767-826F1F7C-93BC-43BC-BE73-43C07D11C18FQ33779152-28B589E5-4C9C-4D4C-8755-C6CBDB586F08Q33826848-D5232F66-E904-450B-BD0D-340E42C33ACBQ33862822-21EEE1DB-4768-404D-99F3-41E15C839714Q33877397-42EB13CA-9619-49B9-BD3D-07D4A9236B73Q33898612-687FFE8C-137E-46E8-A908-B7F08DFB803DQ33917224-54571F06-DA41-45BD-8143-AE35D8C42583Q33960021-294BBFF7-5912-4D4B-8032-0F0638F7D90EQ34005128-0FDDDE6C-8612-4963-B8CD-367111A870A6
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Human T cell responses against melanoma.
@ast
Human T cell responses against melanoma.
@en
type
label
Human T cell responses against melanoma.
@ast
Human T cell responses against melanoma.
@en
prefLabel
Human T cell responses against melanoma.
@ast
Human T cell responses against melanoma.
@en
P2093
P1476
Human T cell responses against melanoma.
@en
P2093
Benoît J Van den Eynde
Pierre G Coulie
Pierre van der Bruggen
Thierry Boon
P304
P356
10.1146/ANNUREV.IMMUNOL.24.021605.090733
P577
2006-01-01T00:00:00Z